| Robert Andrew Miller, LCSW | |
|
1623 E Menlo Blvd, Shorewood, WI 53211-2249 | |
| (414) 967-9689 | |
| (414) 964-2974 |
| Full Name | Robert Andrew Miller |
|---|---|
| Gender | Male |
| Speciality | Counselor - Mental Health |
| Location | 1623 E Menlo Blvd, Shorewood, Wisconsin |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477787984 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | 112123 (Wisconsin) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Robert Andrew Miller, LCSW 1623 E Menlo Blvd, Shorewood, WI 53211-2249 Ph: (414) 967-9689 | Robert Andrew Miller, LCSW 1623 E Menlo Blvd, Shorewood, WI 53211-2249 Ph: (414) 967-9689 |
News Archive
The study, published in the scientific journal Nature, has uncovered a genetic vulnerability present in nearly 10% percent of all breast cancers tumours, and found a way to target this vulnerability and selectively kill cancer cells.
Schering-Plough Corporation has announced that it has extended to stage two an ongoing Phase II clinical study with vicriviroc, its investigational CCR5 antagonist, for use in first-line therapy of adult treatment-naive HIV-infected patients with R5-type virus only. In this study, vicriviroc is being evaluated in a novel nucleoside-sparing regimen that is designed to provide additional options for treatment-naive patients in a once daily regimen, while preserving other drug classes for subsequent lines of treatment.
The latest research shows that patients with heart failure are twice as likely to die if they are admitted to a general hospital ward rather than one specializing in cardiology. Heart failure kills nearly a quarter of a million people in England and Wales every year and about 900,000 people in the UK have the condition that means the heart is weakened and cannot pump blood efficiently. Symptoms include fatigue, breathlessness and swollen ankles, and it can lead to premature death.
NPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced that its Phase 3 pivotal study of GATTEX met the primary efficacy endpoint of reducing parenteral nutrition dependence in patients with adult short bowel syndrome.
› Verified 9 days ago
Jerolynn Bell-scaggs, LPC, ADC Counselor Medicare: Not Enrolled in Medicare Practice Location: 3970 N Oakland Ave Ste 402, Shorewood, WI 53211 Phone: 414-367-8793 | |
Ms. Ellen Abrams Blankenship, MS, NCC, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 4326 N Ardmore Ave, Shorewood, WI 53211 Phone: 414-750-0263 | |
Anika Heaverlo, LPC-IT Counselor Medicare: Not Enrolled in Medicare Practice Location: 3610 N Oakland Ave Ste 3n, Shorewood, WI 53211 Phone: 414-533-7311 | |
Karen Gottlieb, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 2510 E Capitol Dr, Shorewood, WI 53211 Phone: 414-975-8106 | |
Michelle Fahrnow, MS, LPC-IT Counselor Medicare: Not Enrolled in Medicare Practice Location: 4601 N Oakland Ave Ste 221, Shorewood, WI 53211 Phone: 414-202-7754 | |
Dr. Ashley Anne, PHD, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 3950 N Farwell Ave Apt 204, Shorewood, WI 53211 Phone: 920-591-2663 | |
Clarissa Kaye Michaels, Counselor Medicare: Not Enrolled in Medicare Practice Location: 2510 E Capitol Dr, Shorewood, WI 53211 Phone: 414-975-8106 |